Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Condition: Endometrial Cancer Interventions: Drug: Selinexor; Drug: Matching Placebo for selinexor Sponsors: Karyopharm Therapeutics Inc; The GOG Foundation, Inc.; European Network of Gynaecological Oncological Trial; Belgium and Luxembourg Gynaecological Oncology Group; North-Eastern German Society of Gynaecologic Oncology; Multicentre Italian Trials in Ovarian Cancer and Gynecolog ic Malignancies; Spanish Research Group in Ovarian Cancer; The Central and Eastern European Gynecologic Oncology Group; Israel Society of Gynecologic Oncology Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 10, 2022 Category: Research Source Type: clinical trials
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Condition: Endometrial Cancer Interventions: Drug: Selinexor; Drug: Matching Placebo for selinexor Sponsors: Karyopharm Therapeutics Inc; The GOG Foundation, Inc.; European Network of Gynaecological Oncological Trial; Belgium and Luxembourg Gynaecological Oncology Group; North-Eastern German Society of Gynaecologic Oncology; Multicentre Italian Trials in Ovarian Cancer and Gynecolog ic Malignancies; Spanish Research Group in Ovarian Cancer; The Central and Eastern European Gynecologic Oncology Group; Israel Society of Gynecologic Oncology Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 10, 2022 Category: Research Source Type: clinical trials
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Condition: Endometrial Cancer Interventions: Drug: Selinexor; Drug: Matching Placebo for selinexor Sponsors: Karyopharm Therapeutics Inc; The GOG Foundation, Inc.; European Network of Gynaecological Oncological Trial; Belgium and Luxembourg Gynaecological Oncology Group; North-Eastern German Society of Gynaecologic Oncology; Multicentre Italian Trials in Ovarian Cancer and Gynecolog ic Malignancies; Spanish Research Group in Ovarian Cancer; The Central and Eastern European Gynecologic Oncology Group; Israel Society of Gynecologic Oncology Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 10, 2022 Category: Research Source Type: clinical trials
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Condition: Endometrial Cancer Interventions: Drug: Selinexor; Drug: Matching Placebo for selinexor Sponsors: Karyopharm Therapeutics Inc; The GOG Foundation, Inc.; European Network of Gynaecological Oncological Trial; Belgium and Luxembourg Gynaecological Oncology Group; North-Eastern German Society of Gynaecologic Oncology; Multicentre Italian Trials in Ovarian Cancer and Gynecolog ic Malignancies; Spanish Research Group in Ovarian Cancer; The Central and Eastern European Gynecologic Oncology Group; Israel Society of Gynecologic Oncology Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 10, 2022 Category: Research Source Type: clinical trials
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Condition: Endometrial Cancer Interventions: Drug: Selinexor; Drug: Matching Placebo for selinexor Sponsors: Karyopharm Therapeutics Inc; The GOG Foundation, Inc.; European Network of Gynaecological Oncological Trial; Belgium and Luxembourg Gynaecological Oncology Group; North-Eastern German Society of Gynaecologic Oncology; Multicentre Italian Trials in Ovarian Cancer and Gynecolog ic Malignancies; Spanish Research Group in Ovarian Cancer; The Central and Eastern European Gynecologic Oncology Group; Israel Society of Gynecologic Oncology Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 10, 2022 Category: Research Source Type: clinical trials
